Related Experiment Video

Updated: Sep 20, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review

Darren Pan1, Anupama Kumar1, Jodi J Lipof1

  • 1Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.

Expert Opinion on Investigational Drugs
|May 27, 2025
PubMed
Abstract

Insights

G protein-coupled receptor class C group 5 member D (GPRC5D) targeted therapies show promise for multiple myeloma. Research is exploring novel applications and managing toxicities for improved patient outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • G protein-coupled receptor class C group 5 member D (GPRC5D) is a key antigen in multiple myeloma.
  • Several GPRC5D-targeted therapies, including CAR T cells and antibody-drug conjugates, are in development.
  • These agents represent a potential paradigm shift in multiple myeloma treatment.

Purpose of the Study:

  • To review the biology of GPRC5D.
  • To discuss the current and emerging applications of talquetamab in relapsed/refractory multiple myeloma.
  • To examine the landscape of investigational GPRC5D-targeted drugs and their future clinical integration.

Main Methods:

  • Review of current literature on GPRC5D biology and targeted therapies.
  • Analysis of talquetamab's role in multiple myeloma treatment.
  • Exploration of emerging GPRC5D-targeted drug development and clinical trial strategies.

Main Results:

  • Talquetamab is the sole approved GPRC5D-targeted therapy, primarily for BCMA-refractory myeloma.
  • Innovative strategies for GPRC5D targeting are crucial for maximizing therapeutic potential.
  • Investigational trials are exploring combination immunotherapies to overcome resistance.

Conclusions:

  • GPRC5D-targeted therapies offer significant efficacy but carry risks like oral, skin, nail, and cerebellar toxicity.
  • Future research should prioritize optimizing dosing, identifying toxicity biomarkers, and managing adverse events.
  • Balancing efficacy and toxicity is essential for the successful clinical implementation of GPRC5D-targeted treatments.
Keywords:
BCMACAR T cellsGPRC5Dantibody drug conjugatesbispecific antibodiesimmunotherapynovel therapiestrispecific antibodies

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K